Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal Esketamine in Elderly and Younger Adults
NCT02345148Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of esketamine in major depressive disorder (MDD) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration up to 24 hours, Time to Reach Maximum Concentration up to 24 hours and 5 more. Started Dec 2014; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02345148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345148.